Total: $749.91M
Company
(Symbol)#		 Type Of Financing Number Of Shares,
Units Or Warrants (M)		 Amount Raised (M) Investors; Placement Agents; Details
(Date)@
Advanced Life Sciences Holdings Inc. (ADLS) Private placement of common stock 10.2S $20 Advanced Life Sciences Holdings raised $20M through the placement of 10.2M shares priced at $1.90 per share and five-year warrants to buy an additional 5.1M shares at $2.15 each; Lazard Freres acted as lead placement agent, with Susquehanna Financial Group and CRT Capital Group LLC acting as co-placement agents (12/11)
Amarin Corp. plc (AMRN) Private placement of American depositary shares and warrants to buy ADSs; and a private placement of convertible notes 16.3ADSs and W for 8.1ADSs $8.1 Amarin raised $5.4M from investors in exchange for 16.3M ADSs priced at 33 cents each; investors also received five-year warrants to buy 8.lM ADSs at 48 cents each; the second offering brought the company $2.7M through three-year convertible notes; Rodman & Renshaw LLC served as placement agent (12/5)
Ardea Biosciences (IBPI) Private placement of common stock 3S $40 Ardea is placing about 3M shares at $13.25 each with Piper Jaffray & Co. acting as lead placement agent, and Cowen and Co. and Oppenheimer & Co. Inc. acting as co-placement agents (12/20)
AspenBio Pharma Inc. (APPY) Private placement of common stock 2.5S $18.2 AspenBio raised $18.2M through the sale of about 2.5M shares; Oppenheimer & Co. Inc. acted as placement agent (12/26)
AVI BioPharma Inc. (AVII) Registered direct offering 10.7S and W for 5.3S $20.3 AVI Biopharma is raising $20.3M through the sale of about 10.7M shares priced at $1.90 each, plus warrants to purchase an additional 5.3M shares at $2.45 each; Citigroup Global Markets acted as the lead placement agent and Oppenheimer & Co. and Maxim Group LLC served as co-placement agents (12/13)
Cell Therapeutics Inc. (CTIC) Private placement of common stock and warrants W for 3.47S $7 Cell Therapeutics entered into agreements to sell about $7M of its common stock and warrants in a registered offering to institutional investors at $2.02 per share; Rodman & Renshaw LLC acted as the exclusive placement agent (12/21)
ConjuChem Biotechnologies Inc. (Canada; TSX:CJB) Bought deal financing 0.022U $22 ConjuChem closed a financing of $22M through the sale of 22,000 units, each consisting of $1,000 principal amount of 8% convertible unsecured subordinated debentures and 1.6M common share purchase warrants; the financing was led by Dundee Securities Corp., and included Cormark Securities Inc., Macquarie Capital Markets Canada Ltd. and Versant Partners Inc. (12/13)
Cougar Biotechnology Inc. (CGRB) Private placement of common stock 3S $87 Cougar raised $87M through a private placement of 3M shares for $29 each; Leerink Swann LLC served as lead placement agent, with Cowen and Co. LLC and Lazard Freres & Co. LLC acting as co-placement agents (12/17)
Cyclacel Pharmaceuticals Inc. (CYCC) Equity financing facility W for 0.175S $60 Cyclacel secured the option to access up to $60M over the next three years through Kingsbridge Capital Ltd.; it issued five-year warrants to purchase up to 175,000 shares of common stock at $7.17 each (12/11)
Discovery Laboratories Inc. (DSCO) Registered direct offering 10S $25 Discovery Labs raised $25M through the offering; Jefferies & Co. acted as placement agent (12/7)
Helix BioPharma Corp. (Canada; TSX:HBP) Private placement of common stock 10.04S C$16.87($16.56) Helix BioPharma raised $16.56M through the private placement of 10.04M shares priced at C$1.68 each (12/17)
Incyte Corp. (INCY) Equity sale N/A $8.5 Incyte sold its ownership in privatley held Velocity11 in exchange for $8.5M; following a one-year escrow period, it may receive an additional $900,000 (12/21)
Labopharm Inc. (DDSS) Debt refinancing arrangement N/A $15 Labopharm obtained a $25M debt refinancing vehicle through Hercules Technology Growth Capital Inc., securing $15M immediately; the additional $10M is available May 15, 2008, through Nov. 15, 2008 (12/21)
Lixte Biotechnology Holdings Inc. (OTC BB:LIXT) Private placement of common stock 1S $0.65 Lixte raised $650,000 placing 1M shares at 65 cents each; WestPark Capital Inc. acted as placement agent and received five-year warrants to purchase up to 100,000 shares plus five-year incentive warrants to purchase up to an additional 20,000 shares (12/18)
Neoprobe Corp. (OTC BB:NEOP) Private placement N/A $13 Neoprobe raised $13M through Platinum Montaur Life Sciences LLC; the first funding is for $7M in notes due January 2009; Montaur is providing the remaining $6M to support development of Lymphoseek (12/27)
NeurogesX Inc. (NGSX) Private placement of common stock and warrants 4S and W for 1.2S $25 NeurogesX raised $25M, selling about 4M shares at $6.18 each, along with five-year warrants to buy an additional 1.2M shares with an exercise price of $8.034 per share; Pacific Growth Equities LLC served as exclusive placement agent (12/26)
Ondine Biopharma Corp. (Canada; TSX:OBP) Private placement of units 6.3U C$1.5 ($1.3) Ondine closed a private placement generating gross proceeds of C$7M ($6.9M); most of the money was accounted for in the November chart (12/10)
Osiris Therapeutics Inc. (OSIR) Private placement of common stock 0.95S $11.8 Osiris raised $11.8M, selling 950,000 shares at $12.37 each; the shares were placed by Friedli Corporate Finance Inc.; investors were Peter Friedli and Venturetec Inc. (12/20)
ProMetic Life Sciences Inc. (Canada; TSX:PLI) Equity draw-down facility N/A C$15 ($14.9) ProMetic secured a $14.9M equity draw-down facility through Nanuq Investments Ltd. (12/10)
Regeneron Pharmaceuticals Inc. (REGN) Equity investment 12S $312 Sanofi-Aventis Group purchased 12M shares of Regeneron at $26 each as part of a recently signed $1 billion collaboration (12/20)
Titan Pharmaceuticals Inc. (AMEX:TTP) Private placement of common stock 13.3S $21.3 Titan raised $21.3M through the placement of 13.3M shares priced at $1.60 each; Canaccord Adams Inc. and Rodman & Renshaw LLC served as placement agents (12/18)
Virax Holdings Ltd. (Australia; ASX:VHL) Private placement of convertible notes N/A A$2.7 ($2.3) Virax raised $2.3M through the issuance of convertible notes (12/19)
Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange

@ Refers to the date of the press release.

** Denotes the date the item ran in BioWorld International.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.